During Wednesday’s Current trade, Shares of AGCO Corporation (NYSE:AGCO), gain 0.02% to $53.49.
AGCO, Your Agriculture Company, (AGCO), a worldwide manufacturer and distributor of agricultural equipment, declared recently its 2015 Second Quarter Earnings Release Conference Call is planned for Tuesday, July 28th at 10:00 a.m. EDT.
AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The company offers tractors, counting high horsepower tractors that are used on larger farms primarily for row crop production; utility tractors for small- and medium-sized farms, in addition to for specialty agricultural industries comprising dairy, livestock, orchards, and vineyards; compact tractors for small farms, specialty agricultural industries, landscaping, and residential uses; and combines used in harvesting grain crops, such as corn, wheat, soybean, and rice products.
Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), inclined 3.41% to $9.70, during its current trading session.
- Tonix Pharmaceuticals Holding Corp. (TNXP) a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, has designated Mark T. Edgar, PhD to the newly-created position of Senior Vice President of Product Development.
Dr. Edgar brings to Tonix over 25 years of experience in pharmaceutical development and commercialization. He has extensive expertise in advancing research-stage pharmaceutical candidates to commercialization, and has authored chemistry, manufacturing, and controls (CMC) strategies for numerous drug development programs. He joins Tonix from M.T. Edgar Consulting, where he offered pharmaceutical development support for over 46 companies, counting Tonix, across a wide variety of formulations and therapeutic indications since founding the firm in 2003. From 1995 to 2003, Dr. Edgar held several executive level administration positions in the biopharmaceutical industry, counting Executive Vice President of Ancile Pharmaceuticals, Senior Vice President of Product Development of La Jolla Pharmaceutical Company, and Vice President of Development Research of Syntex Corporation, where he began his industry career as a research chemist.
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system in the United States. The company develops TNX-102 SL, a sublingual tablet formulation, which is in Phase 3 clinical development stage for the treatment of fibromyalgia; and Phase 2 clinical development stage for the treatment of post-traumatic stress disorder.
AMETEK, Inc. (NYSE:AME), during its Wednesday’s current trading session decreased -0.08% to $54.66.
AMETEK, Inc. (AME) will issue its second quarter 2015 earnings release before the market opens on Tuesday, August 4, 2015.
AMETEK will webcast its second quarter 2015 investor conference call on Tuesday, August 4, 2015, starting at 8:30 AM ET. The live audio webcast of the conference call will be accessible at www.ametek.com and at www.streetevents.com.
AMETEK, Inc. manufactures electronic instruments and electromechanical devices worldwide. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The EIG segment provides advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, and factory automation markets; and instruments for the laboratory equipment, ultra precision manufacturing, medical, and test and measurement markets. ]
Finally, Nuance Communications Inc. (NASDAQ:NUAN), gained 5.68%, to $17.86.
Nuance Communications, Inc. (NUAN) declared that the Australian Taxation Office (ATO) has accomplished its two-phased deployment of Nuance’s voice biometrics solutions in its call center in an effort to build stronger customer relationships with taxpayers and enhance authentication by replacing intrusive security questioning. With the introduction of its voice biometrics systems, ATO becomes the first organization in Australia to deploy voice biometrics in this manner.
The ATO receives about nine million calls per year from the community, with around 75 percent of these calls requiring an ATO agent to verify the caller’s identity. In addition, the ATO anticipates to receive more than half (4.3) million of these calls within its three-month peak tax period between July and October 2015. Preceding to voice biometrics, when a customer called to conduct a transaction with the ATO, the authentication process involved several steps, putting pressure not only on customers to provide personal details or have the correct documentation in front of them, but also on the ATO’s call center agents, who collectively spent about 75,000 hours each year just trying to verify customers over the phone.
Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. It offers hosted and on-premise solutions and services that provide platforms to generate and distribute clinical documentation through the use of dictation and transcription features; clinical documentation improvement programs; and speech recognition solutions for radiology, cardiology, pathology, and related specialties enabling healthcare providers to dictate, edit, and sign reports without manual transcription.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
